arrow
O

Ombretta Annibali

Fondazione Policlinico Universitario Campus Bio-Medico
H指数:23
被引数:1,773

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infection prevention and management in patients with multiple myeloma treated with bispecific antibodies: a case-based approach for routine clinical practice

多发性骨髓瘤患者接受双特异性抗体治疗时的感染预防与管理:基于病例的方法用于常规临床实践

2026-09-100
OAAI
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study

边缘区淋巴瘤首次复发后的生存情况:国际观察性NF10研究的前瞻性数据

2026-09-060
OAAI
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy

多发性骨髓瘤患者在来那度胺维持治疗后进展的挽救治疗模式:欧洲骨髓瘤网络(EMN)意大利的真实世界研究

2026-09-050
OAAI
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma

利妥昔单抗治疗血液学相关自身免疫性疾病或非霍奇金淋巴瘤患者的感染发生率

2026-05-090
OAAI
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network

更正:Siltuximab 作为特发性多中心性 Castleman 病的一线疗法:一项基于意大利区域网络 SiMuLa 研究的回顾性分析

2026-03-110
OAAI
Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study

丙型肝炎病毒和乙型肝炎病毒在惰性淋巴瘤中:国际观察性NF10研究的预期数据

2026-03-010
OAAI
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)

vemurafenib联合利妥昔单抗治疗复发或难治性毛细胞白血病的真实世界疗效与安全性:一项多中心意大利回顾性研究(HCL-PG03R)

2025-11-140
OAAI
The contribution of IL-10 and IL-6 as potential biomarkers for detecting central nervous system involvement in non-Hodgkin lymphomas

IL-10和IL-6作为检测非霍奇金淋巴瘤中枢神经系统受累的潜在生物标志物的贡献

2025-10-280
OAAI
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience

新诊断多发性骨髓瘤患者使用抗CD38单克隆抗体为基础的一线方案治疗时的感染事件:一项多中心意大利研究经验

2025-10-110
OA
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

来那度胺维持治疗在硼替佐米、沙利度胺和地塞米松(VTD)诱导治疗及自体干细胞移植后的应用:一项意大利真实世界研究,共纳入602例患者

2025-10-011
OAAI
Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

核呼吸因子1在蛋白酶体抑制治疗下促进多发性骨髓瘤细胞存活

Blood
IF23.1
2025-09-100
OAAI
Assessing frailty in patients with relapsed/refractory multiple myeloma: A comparison between the patient-reported frailty phenotype and the International Myeloma Working Group frailty index

评估复发/难治性多发性骨髓瘤患者虚弱程度:患者报告的虚弱表型与国际骨髓瘤工作组虚弱指数的比较

2025-06-040
PRE
Anti CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the RFolSTOP multicentre Italian study ( mar , 10.1007/s00277-025-06295-0 , 2025)

针对COVID-19大流行挑战的滤泡性淋巴瘤抗CD20维持策略:来自意大利多中心RFolSTOP研究的结果 (mar, 10.1007/s00277-025-06295-0, 2025)

2025-04-220
OA
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study

伊沙图昔单抗、泊马度胺和地塞米松 (IsaPd) 在达雷妥尤单抗难治性多发性骨髓瘤患者中的疗效和预后指标: 一项多中心真实世界研究

2025-02-030
OAAI
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
2024-12-100
OAAI
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
2024-06-071
OAAI
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
2024-06-013
OAAI